Announcements
- Idorsia’s JERAYGO (aprocitentan) approved in Europe as first and only ERA for the treatment of resistant hypertension
- Higher cantonal composition authority issues written court decision in respect to the amendments to the terms of the 2024 convertible bonds
- Higher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
- Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
- Idorsia holds its Annual General Meeting of Shareholders
- New data with daridorexant to be presented at SLEEP 2024
- Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
- Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
- Idorsia announces changes to Idorsia Executive Committee and Board of Directors
- Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
More ▼
Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.00 |
---|---|
High | 0.00 |
Low | 0.00 |
Bid | -- |
Offer | -- |
Previous close | 18.85 |
Average volume | -- |
---|---|
Shares outstanding | 189.09m |
Free float | 120.86m |
P/E (TTM) | -- |
Market cap | 404.65m CHF |
EPS (TTM) | -0.3534 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019 07:01 BST.
More ▼